Skip to main content

Table 2 Tumor response at the end of protocol therapy

From: Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Response

FAS (n = 42)

ES (n = 39)

ORR, n (%)

37 (88.1)

37 (94.9)

95%CI

74.4–96.0%

82.7–99.4%

CR, n (%)

27 (64.3)

27 (69.2)

95%CI

48.0–78.4%

52.4–83.0%

PR, n (%)

10 (23.8)

10 (25.6)

SD, n (%)

3 (7.1)

2 (5.1)

NE, n (%)

2 (4.8)

–

  1. FAS Full analysis set, ES Evaluable set, ORR Objective response rate, CI Confidence interval, CR Complete response, PR Partial response, SD Stable disease, NE Not evaluable
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us